India joins ViroVax to boost immunity to biotech covid-19 covacin vaccine

Advertisement

India Biotech has announced that it will work under a licensing agreement with Kansas-based Virovax LLC firm in the United States to increase its vaccine resistance and prolong immunity.

India Biotech, a pharmaceutical company that manufactures 19 Covid vaccines in the country, has announced a license agreement with Kansas-based VeroVax LLC firm in the United States to increase its immunity and lengthen its vaccine immunity.

India Biotech is currently conducting the second phase of human testing of Kovacin. For this he got permission from the Drug Controller General of India (DCGI). The company has worked with the National Institute of Biology on the vaccine.

Advertisement

Read more: Reaction of Indian Covaxin Manufacturer – Immune showed strong reaction after testing on monkeys …

READ  NSA Ajit Doval warns of war between China and Pakistan, from which danger will strike

Chairman and managing director of the company. Krishna Ella said, ‘Vaccines need to develop antibodies to antigens, develop helpers and increase availability, which develops long-term immunity against pathogens. The next step in our relentless efforts to create a safe and long-lasting vaccine is our partnership with ViroVax. ‘

Sunil David, a doctor at Virovax, said, “Virovax India is very happy with the agreement with Biotech. This has been done in collaboration with the National Institutes of Health. Explain that Virovax also received supplemental funding for the development of treatment methods and treatment for the prevention of covid-1 the and for the development of subunit vaccines for its treatment.

READ  BJP minister Pratap Sarangi's big statement says people of the country will get free corona vaccine
Advertisement

Video: Kovaxin Indian, completely safe in early tests: Randeep Guleria

Listen to the latest songs, only at JioSaavn.com

Advertisement

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top